Bio-Techne Corp (NASDAQ:TECH) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, October 31st. Analysts expect Bio-Techne Corp to post earnings of $0.88 per share for the quarter.

Bio-Techne Corp (NASDAQ:TECH) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.10. Bio-Techne Corp had a return on equity of 14.19% and a net margin of 12.93%. The firm had revenue of $156.60 million during the quarter, compared to analyst estimates of $150.25 million. During the same period last year, the company earned $0.92 EPS. Bio-Techne Corp’s quarterly revenue was up 16.2% compared to the same quarter last year. On average, analysts expect Bio-Techne Corp to post $3.72 EPS for the current fiscal year and $4.1 EPS for the next fiscal year.

Shares of Bio-Techne Corp (NASDAQ:TECH) opened at 123.88 on Tuesday. Bio-Techne Corp has a 52 week low of $95.68 and a 52 week high of $125.40. The company has a market capitalization of $4.63 billion, a price-to-earnings ratio of 61.02 and a beta of 0.76. The company’s 50 day moving average price is $122.06 and its 200-day moving average price is $115.43.

In other Bio-Techne Corp news, Director Karen A. Holbrook sold 1,059 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $121.73, for a total transaction of $128,912.07. Following the transaction, the director now directly owns 914 shares in the company, valued at $111,261.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 1,359 shares of company stock worth $164,632 over the last 90 days. 3.40% of the stock is owned by insiders.

A number of research firms recently commented on TECH. Zacks Investment Research cut Bio-Techne Corp from a “buy” rating to a “hold” rating in a report on Tuesday. Citigroup Inc. upped their price objective on Bio-Techne Corp from $125.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday. BidaskClub upgraded Bio-Techne Corp from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Wells Fargo & Company began coverage on Bio-Techne Corp in a report on Thursday, July 13th. They issued a “market perform” rating on the stock. Finally, Deutsche Bank AG upped their price objective on Bio-Techne Corp from $130.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $133.75.

WARNING: “Bio-Techne Corp (TECH) Set to Announce Earnings on Tuesday” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at

About Bio-Techne Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Earnings History for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with's FREE daily email newsletter.